The full-year 2014 BioMeter confirms that 2014 was a banner year for biotechnology. The average BioMeter value for the entire year across all transactions reporting up-front payments and stage of development was $58.7...more
Q3 BioMeter Shows Reemergence of Late Stage Deals -
The average BioMeter value in the third quarter of 2014 was $43.7 million, an increase from the $30.4 million value in the same quarter in 2013, and a slight increase...more
The average BioMeter value in the second quarter of 2014 jumped significantly to $143.4 million, an increase from the $15.9 million value in the first quarter. This included two blockbuster deals, the $1 billion up front paid...more
The MoFo BioMeter for the first quarter of 2014 shows a decrease in average BioMeter value in a quarter dominated by early stage deals. Total dealmaking activity showed an uptick compared to the same quarter in...more
The average BioMeter value in the third quarter of 2013 was $30.4 million, an increase from the $22.2 million value in the second quarter. Like last quarter, Phase 1 and Phase 2 transactions showed very strong results, with...more